Novartis Delves Further into AAV Gene Therapies with US$1.65 B Voyager Deal

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 3 (Table of Contents)

Published: 16 Mar-2022

DOI: 10.3833/pdr.v2022.i3.2678     ISSN: 1756-7874

Section: Licensing



Voyager Therapeutics has entered into an option agreement with Novartis to license next-generation adeno-associated virus capsids for gene therapies targeting undisclosed neurological diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details